Hepatocellular Carcinoma Clinical Trials in Munich
2 recruitingMunich, Germany
Showing 1–2 of 2 trials
Recruiting
Phase 2
Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
Hepatocellular Carcinoma
Enrico De Toni83 enrolled3 locationsNCT05844046
Recruiting
Phase 2
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
Hepatocellular Carcinoma Non-resectable
Ludwig-Maximilians - University of Munich106 enrolled7 locationsNCT04224636